The formal decision makes Narcan the first naloxone-based drug available without a prescription. The FDA approval followed a unanimous recommendation from its independent panel of advisers backing OTC use of Narcan, while suggesting changes to the drug's packaging. The company will have to compete on the price once Narcan begins to face additional OTC competition later this year, said TD Cowen analyst Boris Peaker